Autologous hALK.CAR T cells for neuroblastoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 31 Jan 2025: Trial registered, NCT06803875
  2. 31 Jan 2025: Trial started, NCT06803875

The trials

NCT06803875: Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

State
Under way
Phase
Phase 1 and Phase 2
People
42 planned
Started
31 Jan 2025
Primary completion
31 Dec 2027
Arms
Phase 1 Dose Escalation
Results
None posted
  1. 31 Jan 2025: Trial registered
  2. 31 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.